+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Drugs for Parkinson's Disease Market - Global Forecast 2026-2032- Product Image
Targeted Drugs for Parkinson's Disease Market - Global Forecast 2026-2032- Product Image
Sale

Targeted Drugs for Parkinson's Disease Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6080541
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Drugs for Parkinson's Disease Market is projected to reach USD 4.08 Billion in 2026. It is expected to continue growing at a CAGR of 9.77%, reaching USD 7.13 Billion by 2032.

Targeted Drugs for Parkinson’s Disease: Executive Overview

Targeted drugs for Parkinson’s disease are designed to address specific symptoms, biological pathways, or patient subgroups rather than relying solely on broad dopaminergic replacement. Current care commonly combines levodopa-based therapy with adjunctive medicines, including dopamine agonists, monoamine oxidase-B inhibitors, catechol-O-methyltransferase inhibitors, amantadine, and agents used for non-motor symptoms. Clinical priorities include improving motor control, reducing off-time, limiting dyskinesia, and maintaining treatment tolerability over the course of disease progression.

Treatment Is Shifting Toward More Personalized and Continuous Care

The treatment landscape is being reshaped by earlier recognition of Parkinson’s disease, greater attention to prodromal and non-motor symptoms, and demand for therapies that can provide steadier symptom control. Clinicians increasingly tailor treatment to age, cognitive status, disease stage, fall risk, comorbidities, and medication response. Extended-release formulations, infusion-based delivery, device-assisted treatment, and biomarker-informed clinical development are supporting a move away from one-size-fits-all management. Regulatory and clinical discussions also increasingly distinguish symptomatic benefit from potential disease modification, raising the evidentiary bar for emerging approaches.

Artificial Intelligence Is Strengthening Diagnosis, Monitoring, and Drug Development

Artificial intelligence is contributing to Parkinson’s disease research through digital biomarkers, speech and gait analysis, wearable-sensor data, imaging interpretation, and identification of clinically meaningful patient subgroups. These tools may help detect subtle changes, support remote monitoring, and improve endpoint sensitivity in trials. AI can also assist target discovery, molecule prioritization, protocol design, and adverse-event surveillance. However, clinical adoption depends on prospective validation, representative datasets, explainability, interoperability, privacy safeguards, and evidence that algorithmic outputs improve decisions rather than add complexity.

Regional Insights: Access, Diagnosis, and Delivery Models Vary Widely

In North America, specialist access, advanced neurology services, and digital-health adoption support complex treatment pathways, although affordability and insurance coverage remain important considerations. Europe combines strong clinical research capacity with varied reimbursement, health-technology assessment, and national-care arrangements. Asia-Pacific includes sophisticated specialist systems alongside substantial unmet needs related to diagnosis, rural access, and medicine availability. Latin America faces uneven access to movement-disorder expertise and advanced therapies, with care often concentrated in major urban centers. The Middle East is expanding specialist and hospital capabilities but continues to experience differences in referral pathways and coverage. Africa faces pronounced gaps in diagnosis, specialist workforce, essential medicines, and continuity of care, making scalable primary-care education and referral systems especially important.

Group Insights: Policy Blocs Shape Research and Patient Access

ASEAN markets reflect diverse regulatory systems and healthcare capacities, creating a need for adaptable evidence and distribution strategies. BRICS members span large and varied populations, with priorities that include affordability, domestic capability, specialist training, and access outside major cities. The European Union benefits from collaborative scientific infrastructure while maintaining country-level differences in reimbursement and implementation. G7 countries generally combine advanced research ecosystems with aging populations and heightened expectations for evidence, safety, and patient-centered outcomes. GCC states are investing in modern healthcare infrastructure and specialist services, while workforce development and referral coordination remain relevant. NATO members encompass varied health systems, but many share interests in preparedness, research collaboration, digital interoperability, and continuity of essential neurological care.

Country Insights: National Systems Determine Adoption and Patient Experience

Australia emphasizes specialist-led care, telehealth, and coordination across geographically dispersed communities. Brazil combines major urban expertise with unequal access across regions. Canada’s publicly financed system supports broad clinical coverage but faces jurisdictional differences, specialist wait times, and rural-access challenges. China is expanding neurological capacity and digital-health infrastructure while addressing regional variation in care quality and access. France, Germany, Italy, and Spain have established specialist networks, but reimbursement pathways, regional administration, and treatment adoption differ. India faces a large need for affordable diagnosis, trained specialists, and decentralized care. Japan and South Korea have advanced healthcare systems and strong technology capabilities, alongside aging-population and long-term-care pressures. Mexico continues to develop specialist access beyond major cities. Russia’s care environment is shaped by regional disparities and medicine-access considerations. The United Kingdom benefits from structured clinical guidance and specialist services, while service capacity and geographic variation remain important. The United States offers extensive therapeutic and research options, with access influenced by coverage, cost, specialist availability, and care fragmentation.

Industry Priorities: Build Evidence Around Outcomes, Access, and Real-World Use

Industry leaders should prioritize clinically meaningful outcomes that reflect motor fluctuations, dyskinesia, cognition, sleep, mood, falls, caregiver burden, and quality of life. Development programs should incorporate diverse populations, pragmatic comparators, patient-reported outcomes, and longer-term safety follow-up. Companion digital tools should be validated independently and designed for low-burden use. Access planning should address affordability, administration requirements, diagnostic capacity, specialist training, and supply continuity across high-resource and underserved settings. Partnerships with clinicians, patients, caregivers, regulators, payers, and local health systems can improve implementation while clarifying which treatment benefits matter most in routine practice.

Research Methodology: Evidence-Based Synthesis of the Targeted-Therapy Landscape

This executive summary uses a structured synthesis of established clinical concepts, treatment modalities, healthcare-system considerations, and technology trends relevant to targeted drugs for Parkinson’s disease. The analysis distinguishes symptomatic management, adjunctive treatment, delivery innovation, digital monitoring, and disease-modification research. Regional, group, and country discussion is qualitative and considers clinical capacity, access, regulation, infrastructure, demographics, and care delivery. Claims are framed conservatively, avoid unsupported numerical estimates, and should be supplemented with current peer-reviewed literature, clinical guidelines, regulatory records, trial registries, and local reimbursement sources for investment or clinical decisions.

Conclusion: Progress Depends on Precision, Proof, and Equitable Delivery

Targeted drugs for Parkinson’s disease are developing within a broader transition toward individualized, continuous, and outcome-focused care. Advances in formulation, delivery, digital monitoring, biomarkers, and AI may improve treatment selection and evaluation, but meaningful progress requires robust validation and attention to long-term safety. The strongest strategies will connect therapeutic innovation with practical diagnosis, specialist capacity, affordability, caregiver support, and reliable access across diverse health systems.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Targeted Drugs for Parkinson's Disease Market, by Therapy Type
7.1. Introduction
7.2. Anticholinergics
7.3. Carbidopa Levodopa
7.4. Comt Inhibitors
7.5. Dopamine Agonists
7.6. Mao-B Inhibitors
8. Targeted Drugs for Parkinson's Disease Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Targeted Drugs for Parkinson's Disease Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Transdermal
10. Targeted Drugs for Parkinson's Disease Market, by Disease Stage
10.1. Introduction
10.2. Advanced Stage
10.3. Early Stage
11. Targeted Drugs for Parkinson's Disease Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
11.5. Specialty Clinics
12. Targeted Drugs for Parkinson's Disease Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
13. Targeted Drugs for Parkinson's Disease Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Targeted Drugs for Parkinson's Disease Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Targeted Drugs for Parkinson's Disease Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Acadia Pharmaceuticals, Inc.
17.3. Acorda Therapeutics, Inc.
17.4. C.H. Boehringer Sohn AG & Co. KG
17.5. Eisai Co., Ltd.
17.6. F. Hoffmann-La Roche Ltd.
17.7. GSK plc
17.8. H. Lundbeck A/S
17.9. Impax Laboratories, Inc.
17.10. Kyowa Kirin Co., Ltd.
17.11. Merck & Co., Inc.
17.12. Neurocrine Biosciences, Inc.
17.13. Newron Pharmaceuticals S.p.A.
17.14. Novartis AG
17.15. Orion Corporation
17.16. Pfizer Inc.
17.17. Sunovion Pharmaceuticals, Inc.
17.18. Supernus Pharmaceuticals, Inc.
17.19. Teva Pharmaceutical Industries Ltd.
17.20. UCB S.A.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Targeted Drugs for Parkinson's Disease Market, Years Considered for the Study
FIGURE 2. Global Targeted Drugs for Parkinson's Disease Market, Research Design
FIGURE 3. Global Targeted Drugs for Parkinson's Disease Market, Research Framework
FIGURE 4. Global Targeted Drugs for Parkinson's Disease Market, Data Triangulation
FIGURE 5. Global Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 9. Global Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2025 vs 2032 (%)
FIGURE 13. Global Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Targeted Drugs for Parkinson's Disease Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Targeted Drugs for Parkinson's Disease Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 17. Global Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Targeted Drugs for Parkinson's Disease Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Targeted Drugs for Parkinson's Disease Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Targeted Drugs for Parkinson's Disease Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Targeted Drugs for Parkinson's Disease Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Targeted Drugs for Parkinson's Disease Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Targeted Drugs for Parkinson's Disease Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Targeted Drugs for Parkinson's Disease Market Segmentation & Coverage
TABLE 2. Global Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 3. Global Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Anticholinergics Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Anticholinergics Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Anticholinergics Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Carbidopa Levodopa Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Carbidopa Levodopa Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Carbidopa Levodopa Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Comt Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Comt Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Comt Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Dopamine Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Dopamine Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Dopamine Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Mao-B Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Mao-B Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Mao-B Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 20. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 30. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 40. Global Advanced Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Advanced Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Advanced Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Early Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Early Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Early Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 47. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Homecare Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Homecare Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Homecare Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 60. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 74. North America Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. North America Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 76. North America Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. North America Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 78. North America Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 79. North America Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. North America Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 81. Latin America Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 83. Latin America Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Latin America Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. Latin America Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 86. Latin America Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Latin America Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 88. Europe Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Europe Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 90. Europe Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Europe Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 92. Europe Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 93. Europe Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Europe Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 95. Middle East Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Middle East Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 97. Middle East Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Middle East Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 99. Middle East Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 100. Middle East Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Middle East Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 102. Africa Targeted Drugs for Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Africa Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 104. Africa Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. Africa Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. Africa Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 107. Africa Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Africa Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 109. Global Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 112. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 115. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. ASEAN Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 117. GCC Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. GCC Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 119. GCC Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. GCC Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. GCC Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 122. GCC Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. GCC Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 124. European Union Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. European Union Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 126. European Union Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. European Union Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. European Union Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 129. European Union Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. European Union Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 131. BRICS Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. BRICS Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 133. BRICS Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. BRICS Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. BRICS Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 136. BRICS Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. BRICS Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 138. G7 Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. G7 Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 140. G7 Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. G7 Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. G7 Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 143. G7 Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. G7 Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 145. NATO Targeted Drugs for Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. NATO Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 147. NATO Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. NATO Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. NATO Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 150. NATO Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. NATO Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 152. Global Targeted Drugs for Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. United States Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 154. United States Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 155. United States Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. United States Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 157. United States Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 158. United States Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. United States Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 160. Canada Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 161. Canada Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 162. Canada Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Canada Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. Canada Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 165. Canada Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. Canada Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 167. Mexico Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 168. Mexico Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 169. Mexico Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Mexico Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. Mexico Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 172. Mexico Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Mexico Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. Brazil Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 175. Brazil Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 176. Brazil Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Brazil Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 178. Brazil Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 179. Brazil Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Brazil Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 181. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 182. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 183. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 186. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. United Kingdom Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 188. Germany Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 189. Germany Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 190. Germany Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Germany Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 192. Germany Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 193. Germany Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Germany Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 195. France Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 196. France Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 197. France Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. France Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. France Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 200. France Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. France Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 202. Russia Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 203. Russia Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 204. Russia Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Russia Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. Russia Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 207. Russia Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Russia Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 209. Italy Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 210. Italy Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 211. Italy Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Italy Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. Italy Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 214. Italy Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Italy Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 216. Spain Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 217. Spain Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 218. Spain Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. Spain Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 220. Spain Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 221. Spain Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. Spain Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 223. China Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 224. China Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 225. China Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. China Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. China Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 228. China Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. China Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 230. India Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 231. India Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 232. India Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. India Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 234. India Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 235. India Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. India Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 237. Japan Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 238. Japan Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 239. Japan Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. Japan Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 241. Japan Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 242. Japan Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. Japan Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 244. Australia Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 245. Australia Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 246. Australia Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. Australia Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 248. Australia Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 249. Australia Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. Australia Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 251. South Korea Targeted Drugs for Parkinson's Disease Market Size, 2017-2032 (USD Million)
TABLE 252. South Korea Targeted Drugs for Parkinson's Disease Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 253. South Korea Targeted Drugs for Parkinson's Disease Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. South Korea Targeted Drugs for Parkinson's Disease Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. South Korea Targeted Drugs for Parkinson's Disease Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 256. South Korea Targeted Drugs for Parkinson's Disease Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. South Korea Targeted Drugs for Parkinson's Disease Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 258. Global Targeted Drugs for Parkinson's Disease Market Share, by Key Player, 2025
TABLE 259. Global Targeted Drugs for Parkinson's Disease Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Acadia Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • C.H. Boehringer Sohn AG & Co. KG
  • Eisai Co., Ltd.
  • F. Hoffmann‑La Roche Ltd.
  • GSK plc
  • H. Lundbeck A/S
  • Impax Laboratories, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Newron Pharmaceuticals S.p.A.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sunovion Pharmaceuticals, Inc.
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Related Topics

Related Reports

Parkinson's Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Parkinson's Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Anti-Parkinson's Disease Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-Parkinson's Disease Drugs Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Parkinson's Disease Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035) - Product Image

Parkinson's Disease Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.